The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ...

Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response assessments and follow-up. In addition, Xilio continues to enroll patients in ...

“In 2025, we will be sharply focused on maximizing the revenue potential for LOQTORZI while advancing the development of our pipeline, including our first-in-class IL-27 antagonist, casdozokitug, and ...

Next-Generation Immunomodulators BNT327 is a bispecific antibody candidate combining PD-L1 checkpoint ... trial (NCT06712355 ) evaluating BNT327 plus chemotherapy compared to atezolizumab plus ...

James Harrison earned the nickname “The Man With the Golden Arm” because his blood had a rare antibody that may have helped more than two million babies in Australia. By Amelia Nierenberg ...

Harrison's plasma contained the rare antibody Anti-D, also known as Rhesus D antibody, which is used to make the medication given to mothers whose blood is at risk of attacking their fetuses.